Axcella, which is developing amino acid-based therapies to treat liver and other diseases, added insider buying to its upcoming $75 million IPO. The company still plans to sell 3.6 million shares at a price of $20-$22, but now states that certain of its existing shareholders have indicated an interest in purchasing $43 million (57%) of the deal. The company's largest shareholders are Flagship Pioneering, Fidelity, Nestlé Health Science, and Gurnet Point Capital. Goldman Sachs, J.P. Morgan, and SVB Leerink are the underwriters on the offering.
